These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 25912112)
21. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Averna M; Missault L; Vaverkova H; Farnier M; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Taggart W; Brudi P Diab Vasc Dis Res; 2011 Oct; 8(4):262-70. PubMed ID: 21859750 [TBL] [Abstract][Full Text] [Related]
22. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
23. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study. Huang JC; Lee TY; Liou MJ; Lin CM; Pei D; Chen ZC; Liu RT; Kwok CF Curr Med Res Opin; 2011 Aug; 27(8):1645-51. PubMed ID: 21699369 [TBL] [Abstract][Full Text] [Related]
24. Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes. Ganesan S; Ito MK Metab Syndr Relat Disord; 2013 Aug; 11(4):251-5. PubMed ID: 23496027 [TBL] [Abstract][Full Text] [Related]
25. Statins, risk of diabetes, and implications on outcomes in the general population. Wang KL; Liu CJ; Chao TF; Huang CM; Wu CH; Chen SJ; Chen TJ; Lin SJ; Chiang CE J Am Coll Cardiol; 2012 Oct; 60(14):1231-8. PubMed ID: 22884288 [TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients. Furman A; Meier JL; Malmstrom RA; Lopez JR; Schaefer S Am J Manag Care; 2011; 17(8):538-44. PubMed ID: 21851141 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Kato ET; Cannon CP; Blazing MA; Bohula E; Guneri S; White JA; Murphy SA; Park JG; Braunwald E; Giugliano RP J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151034 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296 [TBL] [Abstract][Full Text] [Related]
29. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Virani SS; Akeroyd JM; Nambi V; Maddox TM; Gillette MA; Michael Ho P; Rumsfeld J; Petersen LA; Ballantyne CM Am J Med; 2015 Nov; 128(11):1253-6. PubMed ID: 26071828 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691 [TBL] [Abstract][Full Text] [Related]
31. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597 [TBL] [Abstract][Full Text] [Related]
32. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Pokharel Y; Chinnakondepalli K; Vilain K; Wang K; Mark DB; Davies G; Blazing MA; Giugliano RP; Braunwald E; Cannon CP; Cohen DJ; Magnuson EA Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506979 [TBL] [Abstract][Full Text] [Related]
33. Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Berthold HK; Berneis K; Mantzoros CS; Krone W; Gouni-Berthold I Scand Cardiovasc J Suppl; 2013 Feb; 47(1):20-7. PubMed ID: 23013513 [TBL] [Abstract][Full Text] [Related]
34. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Reckless JP; Henry P; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO; Lis K; Brudi P; Allen C Int J Clin Pract; 2008 Apr; 62(4):539-54. PubMed ID: 18266852 [TBL] [Abstract][Full Text] [Related]
35. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E; J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343 [TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Suzuki H; Watanabe Y; Kumagai H; Shuto H Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):306-15. PubMed ID: 24280596 [TBL] [Abstract][Full Text] [Related]
37. Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe. Rudofsky G; Reismann P; Groener JB; Djuric Z; Fleming T; Metzner C; Grafe IA; Bierhaus A; Nawroth PP Atherosclerosis; 2012 Jul; 223(1):190-6. PubMed ID: 22633472 [TBL] [Abstract][Full Text] [Related]